PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

To assess the efficacy and safety of PI3K/AKT/mTOR inhibitor-containing regimens in women with locally advanced, metastatic or recurrent endometrial cancer.

This is a protocol.

Share/Save